# Efficacy Study of Cilostazol and Aspirin on Cerebral Small Vessel Disease

Study · id `cardio:ct-nct01932203` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01932203](<https://clinicaltrials.gov/study/NCT01932203>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT01932203

Browse, organ or system: Blood vessels; Brain  
Browse, condition area: Stroke  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 255 participants.

## Technical summary

Registry record NCT01932203. Randomized; quadruple masking; primary purpose treatment. Start 2013-07-17 (actual); primary completion 2019-08-06 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 255 participants (enrolled count; ClinicalTrials.gov record NCT01932203, source copy `cardio:ctgov-nct01932203-2019-08-08`, retrieved 2026-11-18)
- Started: 2013-07-17 (actual) (ClinicalTrials.gov record NCT01932203, source copy `cardio:ctgov-nct01932203-2019-08-08`, retrieved 2026-11-18)
- Primary completion: 2019-08-06 (actual) (ClinicalTrials.gov record NCT01932203, source copy `cardio:ctgov-nct01932203-2019-08-08`, retrieved 2026-11-18)
- Completion: 2019-08-31 (anticipated) (ClinicalTrials.gov record NCT01932203, source copy `cardio:ctgov-nct01932203-2019-08-08`, retrieved 2026-11-18)
- Countries: South Korea (ClinicalTrials.gov record NCT01932203, source copy `cardio:ctgov-nct01932203-2019-08-08`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01932203-2019-08-08`, retrieved 2026-11-18)

## The registry's words

- Brief title: Efficacy Study of Cilostazol and Aspirin on Cerebral Small Vessel Disease
- Acronym: Challenge
- Condition: Cerebral Small Vessel Disease
- Intervention (Drug): aspirin
- Intervention (Drug): cilostazol
- Lead sponsor: Inha University Hospital
- Lead sponsor class: OTHER
- Collaborator: Otsuka Pharmaceutical Development & Commercialization, Inc.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Cerebral small vessel disease (`cardio:cerebral-small-vessel-disease`)
- Registry intervention name matches this record: Aspirin (`core:aspirin`)
- Registry lists this organization as the lead sponsor: Inha University Hospital (`cardio:org-inha-university-hospital`)
- Registry lists this organization as a collaborator: Otsuka Pharmaceutical Development & Commercialization, Inc. (`cardio:org-otsuka-pharmaceutical-development-commercialization-inc`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Cilostazol Versus Aspirin on White Matter Changes in Cerebral Small Vessel Disease: A Randomized Controlled Trial (`cardio:pubmed-34781708`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 076ac43d0daa97a94d73db423cb2a6b4cc6930e9cca442fe25093d5da5d20f17
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
